Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Asia Pacific Innovation Center, Senior Director
Company: Johnson & Johnson
个人简介:
Han Dai is Senior Director, New Ventures, Johnson & Johnson Innovation Asia Pacific, responsible for developing and implementing Innovation strategies and the identifying and evaluating of external opportunities in China.   Han has 20 years’ experience in Pharma/Biotech industry with track records of successful leadership in small molecule & biologics drug discovery & development and high-profile publications. Prior to joining Johnson & Johnson Innovation, Han was Executive Director at BeiGene. Prior to that, he held multiple roles with increasing responsibilities as Scientific Leader and GSK Fellow of Protein Degradation DPU/Future Pipeline Discovery team at GlaxoSmithKline US headquarter.  Han received his Ph.D. in Molecular Biophysics from UT Southwestern Medical Center as Frank and Sara McKnight fellow, and his B.S. in Biochemistry from Department for Intensive Instruction, Nanjing University. Han completed his postdoctoral training in Harvard Medical School and HHMI as Helen Hay Whitney fellow. He has published more than 40 papers, book chapter, abstracts and patents in reputable journals and conferences. Han served as Scientific Advisory Board member of the Chemical Probes Portal, Full Faculty Member of F1000 Drug Discovery & Design Section, President of Sino-American Pharmaceutical Professional Association – Greater Philadelphia (SAPA-GP) and VP of SAPA-HQ. He is also a visiting professor at High Magnetic Field Laboratory of the Chinese Academy of Sciences (CHMFL).
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Senior Partner
Company: TF Capital
个人简介:
Dr. Ni Lin, Senior Partner of TF Capital, has more than 20 years of industry experience in the life sciences field; such as new drug research scientist, multinational company manager and venture capitalist. Prior to joining TF Capital, she was the Managing Director of SDIC (Stated Development and Investment Corporation) and 6 Dimensions Capital. She was also the director of WuXi AppTec’s corporate investment department managing corporate strategic M&A and venture capital funds. She has led and participated in more than 20 investments in the life sciences and medical fields in China and in the United States, of which nearly half have been exited. Prior to becoming a VC, she was , responsible for Pfizer's R&D cooperation and expansion in Japan as a member of Pfizer's business development department, and supporting Pfizer's animal health division's product launch, cooperation, strategic investment and M&A in the Asia Pacific region. Dr. Ni started her career at Bayer’s drug development center in Kyoto. She has a bachelor’s degree in biology from East China Normal University, and a master's and doctorate degree in pharmacology from Osaka University in Japan.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Head of Research Beyond Borders China
Company: Boehringer Ingelheim
个人简介:
Weiyi Zhang is currently the Sr. Director and head of external innovation China at Boehringer Ingelheim, and she is responsible for setting up collaborations in China for research functions at BI. Weiyi gained her bachelor degree in Biology at Xiamen University in 2001. She joined international Max-Planck research school in chemical biology in 2003 and studied function of olfactory G-protein coupled receptor in non-olfactory tissues. She obtained her Ph.D in cell biology from Ruhr-University Bochum in 2007. Since 2008, Weiyi started postdoc training in functional study of orphan GPCRs in central neural system at both National Institute of Biological Sciences and the University of Hong Kong.Before joining Boehringer Ingelheim, Weiyi has led a cell biology group at BioDuro-PPD in Beijing since 2009, focusing on cell-based assays and integrated early drug discovery programs for various pharmaceutical companies. Then she has led the monoclonal antibody research group at Bio-Rad Laboratory in Shanghai from 2012 to 2013. From 2013 to 2016, Weiyi was the associate director at Innovation Center China of Global Drug Discovery at Bayer Healthcare.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Head of External R&D Asia Pacific
Company: Sanofi Pasteur
个人简介:
As the Regional Head of External R&D, Sean is responsible for the identification and evaluation vaccine-related opportunities developed by Asia-Pacific countries to support Sanofi Pasteur’s global pipeline. Under his leadership, Sanofi Pasteur has completed research agreements with the University of Melbourne, Xiamen University and Chinese Academy of Sciences, initiated feasibility studies with biotech companies from South Korea, Japan, and USA, and executed an exclusive global licensing agreement with Xiamen Innovax on its recombinant rotavirus vaccine candidate. Sean has 20 years of extensive vaccine product and business development experience in biotech, regional pharma, and multinational companies. Before joining Sanofi Pasteur, Sean was Co-Founder and Chief Operating Officer at Altravax. from May 2013 to September 2015 and Executive Director in Vaccine Research at Simcere Pharmaceutical Group from February 2010 to April 2013. Prior to Simcere, he worked as a Senior Scientist and Project Leader at Maxygen. for 9 years. Sean has led discovery research and preclinical development of multiple prophylactic and therapeutic vaccine candidates, conducted pre-clinical meetings with FDA, and achieved a clinical trial approval by CDE. Since 2010, Sean has also led business development activities with academic institutions and industrial partners, playing a lead role in evaluation, negotiation, and management of licensing opportunities. Sean received his Ph.D. degree in Biological Sciences from the University of Delaware, M.S degree in Microbiology from the Institute of Microbiology, Chinese Academy of Sciences, and B.S. degree in Microbiology from Shandong University. He received his postdoctoral training at Columbia University Columbia University College of Physicians & Surgeons from 1998 to 2001.